So Sir Pascal may seem an unlikely ally of Donald Trump, who as America’s president has slashed public spending on scientific ...

It plans to invest $50 billion in the US over five years, including building its largest-ever manufacturing facility in ...

AstraZeneca’s CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing ...

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly transferring manufacturing” across the Atlantic.

In an earnings call on July 29th, in which the company reported a 13% increase in half-year profits, he said about Britain ...

With its latest $50 billion U.S. manufacturing investment and record U.S. growth, is British AstraZeneca looking at itself as ...

Today’s Forbes CFO newsletter focuses on Aradhana Sarin’s journey from treating patients to becoming what she calls a ...

AstraZeneca CFO Aradhana Sarin tells Yahoo Finance the company sees US innovation threatened by China, even as it commits $50 ...

AstraZeneca Plc reported better-than-expected sales and rising profit for the second quarter, spurred by its stable of cancer medicines and growth in the US. Chief Executive Officer Pascal Soriot has ...

Speaking from Astra's offices in New York, Sir Pascal Soriot (pictured) said it was 'global', but it was 'very much rooted ...